

CLINMISKIN AD GEL

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for CLINMISKIN AD GEL [Adapalene & Clindamycin Phosphate Gel]

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

MECHANISM OF ACTION: Adapalene is a chemically stable, retinoid-like compound. Biochemical and pharmacological profile studies have demonstrated that Adapalene is a modulator of cellular differentiation, keratinization and inflammatory processes, all of which represent important features in the pathology of acne vulgaris. Mechanistically, Adapalene binds to specific retinoid acid nuclear receptors but does not bind to the Cytosolic Receptor Protein. Although the exact mode of action of Adapalene is unknown, it is suggested that topical Adapalene may normalize the differentiation of follicular epithelial cells resulting in decreased microcomedone formation. Clindamycin have been shown to have in vitro activity against propionibacterium acnes - an organism which has been associated with acne vulgaris.

INDICATION: It is indicated for the treatment of acene vulgaris

DOSAGE AND ADMINISTRATION: Clinmiskin Ad Gel should be applied once a day to affected areas after washing in the evening before retiring. A thin film of the Gel should be applied, avoiding eyes, lips, and mucous membranes. During the early weeks of therapy, an apparent exacerbation of acne may occur. This is due to the action of the medication on previously unseen lesions and should not be considered a reason to discontinue therapy. Therapeutic results should be noticed after eight to twelve weeks of treatment.

CONTRAINDICATION: Clinmiskin Ad Gel should not be administered to Individuals who are hypersensitive to Adapalene, Clindamycin, Lincomycin or any of the components in the Gel base. In individuals with a history of regional enteritis or ulcerative colitis, or a history of antibiotic associated colitis.

WARNINGS & PRECAUTIONS Use of Clinmiskin Ad Gel should be discontinued if hypersensitivity, irritation, or significant diarrhoea occurs. Avoid sun exposure, contact with eyes and mucous membranes, and application on damaged or sunburned skin. Mild skin reactions may occur initially and usually lessen with continued use, but treatment should be reduced or stopped if severe.

DRUG INTERACTIONS: As Clinmiskin Ad Gel has the potential to produce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime) should be approached with caution. Particular caution should be exercised in using preparations containing Sulfur, Resorcinol, or Salicylic Acid in combination with Clinmiskin® Ad Gel. If these preparations have been used, it is advisable not to start therapy with Clinmiskin® Ad Gel until the effects of such preparations in the skin have subsided.

ADVERSE REACTIONS: Erythema,s scaling, dryness, pruritus, burning, oily skin, contact dermatitis, stinging of the eye, abdominal pain, gram-negative folliculitis.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

IN/ CLINMISKIN AD GEL 5 gm and 20 gm/NOV-23/01/ABPI

(Additional information is available on request)